Respicardia Stock

respicardia.comHealthcareFounded: 2006Funding to Date: $153.45MM

Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health.

Register for Details

For more details on financing and valuation for Respicardia, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Respicardia.

Register Today


Management Team

Timothy Hauch
Chief Financial Officer
Todd Goblish
Vice President, Research & Development
Peter Sommerness
Chief Executive Officer
Linda Nelson
Vice President, Clinical Affairs
Bonnie Labosky
Chief Executive Officer, Board Member & President
Frank Piskolich JD
General and IP Counsel
Robin Germany MD
Chief Medical Officer

Board Members

Kristine Johnson
Affinity Capital Management
Thomas Weldon
Accuitive Medical Ventures
William Abraham MD
Kirk Nielsen
Versant Venture Management
Wilfred Jaeger MD
Three Arch Partners
Zack Scott MD
Revelation Partners
Kevin Wasserstein
Versant Venture Management
Scott Ward
Edward Andrle

Other companies like Respicardia in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Respicardia Inc. has received a $20 million investment from Sorin Group and sold select European distribution rights for its implantable sleep apnea device to the Italian medical-device company.
Sorin GroupĀ (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.